Your browser doesn't support javascript.
loading
Peripheral T-cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK-negative.
Ganapathi, Karthik A; Nicolae, Alina; Egan, Caoimhe; Geng, Huimin; Xi, Liqiang; Pack, Svetlana D; McFadden, Jason R; Raffeld, Mark; Jaffe, Elaine S; Pittaluga, Stefania.
Affiliation
  • Ganapathi KA; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Nicolae A; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Egan C; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Geng H; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Xi L; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Pack SD; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • McFadden JR; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Raffeld M; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Jaffe ES; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Pittaluga S; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Br J Haematol ; 204(5): 1862-1871, 2024 May.
Article in En | MEDLINE | ID: mdl-38613165
ABSTRACT
Peripheral T-cell lymphomas (PTCL) are morphologically and biologically heterogeneous and a subset expresses CD30, including anaplastic large cell lymphomas (ALCL) and a minority of PTCL, not otherwise specified (PTCL, NOS). ALCL with ALK translocations (ALCL, ALK+) are readily identified by routine diagnostic methods, but differentiating ALCL without ALK translocation (ALCL, ALK-) and PTCL, NOS expressing CD30 (PTCL CD30+) can be challenging. Furthermore, rare PTCL co-express CD30 and CD15 (PTCL CD30+CD15+); some resemble ALCL, ALK- while others resemble classic Hodgkin lymphoma. To explore the relationship between PTCL CD30+CD15+ and ALCL, ALK-, we analysed 19 cases of PTCL with CD30 expression, previously diagnosed as ALCL, ALK- (nine cases) and PTCL CD30+CD15+ (10 cases) for DUSP22/IRF4 rearrangements, coding RNA expression and selected transcriptome analysis using the NanoString nCounter gene expression analysis platform. Unsupervised clustering showed no clear segregation between ALCL, ALK- and PTCL CD30+CD15+. Three cases previously classified as PTCL CD30+CD15+ showed DUSP22/IRF4 rearrangements, favouring a diagnosis of ALCL, ALK-. Our results suggest that cases previously designated PTCL CD30+CD15+, likely fall within the spectrum of ALCL, ALK-; additionally, a subset of ALCL, ALK- with DUSP22/IRF4 rearrangement expresses CD15, consistent with previous reports and expands the immunophenotypic spectrum of this lymphoma subgroup.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, T-Cell, Peripheral / Lewis X Antigen / Lymphoma, Large-Cell, Anaplastic / Ki-1 Antigen / Anaplastic Lymphoma Kinase Limits: Female / Humans / Male Language: En Journal: Br J Haematol Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, T-Cell, Peripheral / Lewis X Antigen / Lymphoma, Large-Cell, Anaplastic / Ki-1 Antigen / Anaplastic Lymphoma Kinase Limits: Female / Humans / Male Language: En Journal: Br J Haematol Year: 2024 Document type: Article Affiliation country: